Tbio IRF7 Interferon regulatory factor 7

Protein Summary

Description

Key transcriptional regulator of type I interferon (IFN)-dependent immune responses and plays a critical role in the innate immune response against DNA and RNA viruses. Regulates the transcription of type I IFN genes (IFN-alpha and IFN-beta) and IFN-stimulated genes (ISG) by binding to an interferon-stimulated response element (ISRE) in their promoters. Can efficiently activate both the IFN-beta (IFNB) and the IFN-alpha (IFNA) genes and mediate their induction via both the virus-activated, MyD88-independent pathway and the TLR-activated, MyD88-dependent pathway. Required during both the early and late phases of the IFN gene induction but is more critical for the late than for the early phase. Exists in an inactive form in the cytoplasm of uninfected cells and following viral infection, double-stranded RNA (dsRNA), or toll-like receptor (TLR) signaling, becomes phosphorylated by IKBKE and TBK1 kinases. This induces a conformational change, leading to its dimerization and nuclear localization where along with other coactivators it can activate transcription of the type I IFN and ISG genes. Can also play a role in regulating adaptive immune responses by inducing PSMB9/LMP2 expression, either directly or through induction of IRF1. Binds to the Q promoter (Qp) of EBV nuclear antigen 1 a (EBNA1) and may play a role in the regulation of EBV latency. Can activate distinct gene expression programs in macrophages and regulate the anti-tumor properties of primary macrophages. IRF7 encodes interferon regulatory factor 7, a member of the interferon regulatory transcription factor (IRF) family. IRF7 has been shown to play a role in the transcriptional activation of virus-inducible cellular genes, including interferon beta chain genes. Inducible expression of IRF7 is largely restricted to lymphoid tissue. Multiple IRF7 transcript variants have been identified, although the functional consequences of these have not yet been established. [provided by RefSeq, Jul 2008]

Uniprot Accession IDs

• Q92985
• B9EGL3
• O00331
• O00332
• O00333
• O75924
• Q9UE79
• IRF-7

Gene Name

• IRF7

Ensembl ID

• ENST00000330243
• ENSP00000329411
• ENSG00000185507
• ENST00000348655
• ENSP00000331803
• ENST00000397566
• ENSP00000380697
• ENST00000397574
• ENSP00000380704
• ENST00000469048
• ENSP00000434607
• ENST00000525445
• ENSP00000434009
• ENST00000533182
• ENSP00000433903
• ENST00000612534
• ENSP00000479615
• ENSG00000276561
• ENST00000621391
• ENSP00000480358
• ENST00000632827
• ENSP00000488039
• ENST00000633274
• ENSP00000488591
• ENST00000633943
• ENSP00000488666
• ENST00000634105
• ENSP00000488581

Symbol

• IMD39
• IRF-7
• IRF7A
• IRF7B
• IRF7C
• IRF7H
• IRF-7H

Knowledge Table

Most Knowledge About	Knowledge Value (0 to 1 scale)
virus perturbation	1
biological process	0.98
gene perturbation	0.91
protein domain	0.85
hub protein	0.79

Protein Classes

PANTHER Classes

Protein / Transcription Factor / Interferon Regulatory Factor 7

Protein / Nucleic Acid Binding / Interferon Regulatory Factor 7

Protein / ... / Winged Helix/forkhead Transcription Factor / Interferon Regulatory Factor 7

DTO Classes

Protein / Transcription Factor / Helix-turn-helix Transcription Factor / Winged Helix/forkhead Transcription Factor / Interferon Regulatory Factor 7

IDG Development Level Summary

Tdark

These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:

Pubmed score: 526.95   (req: < 5)

Gene RIFs: 120   (req: <= 3)

Antibodies: 558   (req: <= 50)

Tbio

These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:

Pubmed score: 526.95   (req: >= 5)

Gene RIFs: 120   (req: > 3)

Antibodies: 558   (req: > 50)

- OR - satisfy the following criterion:

Gene Ontology Terms: 32

Tchem

Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions

Active Ligand: 0

Tclin

Target has at least one approved drug - AND - satisfies the preceding conditions

Active Drug: 0